Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.52 |
| ▸ | MAPT | P10636 | 8/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | MPI | P34949 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3159167 | 0.83 | ALDH1A1 (0.71) | ALDH1A1MAPTHSD17B10HRH3KMT2A | |
| SCHEMBL6292088 | 0.81 | ALDH1A1 (0.49) | ALDH1A1MAPTHSD17B10HRH3KMT2A | |
| SCHEMBL932621 | 0.81 | ATM (0.57) | ALDH1A1MAPTHSD17B10HRH3KMT2A | |
| SCHEMBL12947818 | 0.80 | KMT2A (0.69) | ALDH1A1MAPTHSD17B10HRH3KMT2A | |
| SCHEMBL1927765 | 0.80 | ALDH1A1 (0.70) | ALDH1A1MAPTHSD17B10HRH3KMT2A | |
| SCHEMBL6631154 | 0.80 | ALDH1A1 (0.56) | ALDH1A1MAPTHSD17B10HRH3KMT2A | |
| SCHEMBL14305323 | 0.80 | ALDH1A1 (0.56) | ALDH1A1MAPTHSD17B10HRH3KMT2A | |
| SCHEMBL18587751 | 0.80 | ALDH1A1 (0.56) | ALDH1A1MAPTHSD17B10HRH3KMT2A | |
| SCHEMBL21303901 | 0.80 | ALDH1A1 (0.56) | ALDH1A1MAPTHSD17B10HRH3KMT2A | |
| SCHEMBL4043152 | 0.80 | ALDH1A1 (0.56) | ALDH1A1MAPTHSD17B10HRH3KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210403459-A1 | SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS AND USES THEREOF | Karyopharm Therapeutics Inc. | 2021-12-30 | — | — | US | claimed |
| CN-108440515-B | Substituted benzofuranyl and benzoxazolyl compounds and uses thereof | 卡尔约药物治疗公司 | 2022-05-03 | — | — | CN | disclosed |
| US-20210403459-A1 | SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS AND USES THEREOF | Karyopharm Therapeutics Inc. | 2021-12-30 | — | — | US | disclosed |
| US-11008309-B2 | Substituted benzofuranyl and benzoxazolyl compounds and uses thereof | Karyopharm Therapeutics Inc. (US) | 2021-05-18 | — | — | US | disclosed |
| US-20200102292-A1 | SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS AND USES THEREOF | Karyopharm Therapeutics Inc. | 2020-04-02 | — | — | US | disclosed |
| US-10399963-B2 | Substituted benzofuranyl and benzoxazolyl compounds and uses thereof | Karyopharm Therapeutics Inc. (US) | 2019-09-03 | — | — | US | disclosed |
| US-20180319779-A1 | SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS AND USES THEREOF | Karyopharm Therapeutics Inc. | 2018-11-08 | — | — | US | disclosed |
| US-9856241-B2 | Substituted benzofuranyl and benzoxazolyl compounds and uses thereof | Karyopharm Therapeutics Inc. (US) | 2018-01-02 | — | — | US | disclosed |
| US-20160368904-A1 | SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS AND USES THEREOF | Karyopharm Therapeutics Inc. | 2016-12-22 | — | — | US | disclosed |
| EP-3016946-A1 | SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS AND USES THEREOF | Karyopharm Therapeutics, Inc. (US) | 2016-05-11 | — | — | EP | disclosed |
| CN-105492437-A | Substituted benzofuranyl and benzoxazolyl compounds and uses thereof | KARYOPHARM THERAPEUTICS INC | 2016-04-13 | — | — | CN | disclosed |
| EP-2948450-A1 | METALLOENZYME INHIBITOR COMPOUNDS | Viamet Pharmaceuticals, Inc. (US) | 2015-12-02 | — | — | EP | disclosed |
| WO-2015003166-A1 | SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS AND USES THEREOF | Karyopharm Therapeutics Inc. (US) | 2015-01-08 | — | — | WO | disclosed |
| WO-2014117090-A1 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS, INC. (US) | 2014-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160368904-A1 | SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS AND USES THEREOF | BCL6, MALT1, BTK | ALDH1A1 457/4885MAPT 3332/4885HSD17B10 934/4885 |
| US-20180319779-A1 | SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS AND USES THEREOF | BCL6, MALT1, BTK | ALDH1A1 503/4885MAPT 3720/4885HSD17B10 1063/4885 |
| US-11008309-B2 | Substituted benzofuranyl and benzoxazolyl compounds and uses thereof | BCL6, MALT1, BTK | ALDH1A1 503/4885MAPT 3720/4885HSD17B10 1063/4885 |
| US-10399963-B2 | Substituted benzofuranyl and benzoxazolyl compounds and uses thereof | BCL6, MALT1, BTK | ALDH1A1 503/4885MAPT 3720/4885HSD17B10 1063/4885 |
| US-20210403459-A1 | SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS AND USES THEREOF | BCL6, MALT1, BTK | ALDH1A1 503/4885MAPT 3720/4885HSD17B10 1063/4885 |
| US-20200102292-A1 | SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS AND USES THEREOF | BCL6, MALT1, BTK | ALDH1A1 503/4885MAPT 3720/4885HSD17B10 1063/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.